

# Cytochrome-c-Oxidase Deficient Cardiomyocytes in the Human Heart —An Age-Related Phenomenon

## *A Histochemical Ultracytochemical Study*

J. Müller-Höcker

*From the Pathologisches Institut der Universität München,  
München, West Germany*

*Cytochrome-c-oxidase, the terminal enzyme of the respiratory chain, was studied in 140 hearts from men obtained at autopsy revealing randomly distributed cardiomyocytes without enzyme activity. The expression of the defect was independent of an underlying heart disease and was observed both in normal hearts and in hearts with hypertrophy and/or coronary arteriosclerosis. In contrast, age was a discriminating factor: The defects occurred sporadically in the second decade, but were regularly present from the sixth decade on. Also, the number of defects/sq cm (defect density) increased with age from 2 to 3 in the second and third decade, to about 50 defects in advanced age. Irrespective of the defect density, the enzyme defect always affected isolated cardiomyocytes and ended abruptly at the intercalated disc of neighboring heart muscle cells, as revealed by ultracytochemistry. The results indicate that cytochrome-c-oxidase deficient heart muscle cells represent a degenerative lesion associated with cellular ageing and may be involved in the reduction of myocardial contractile ability in senescence. (Am J Pathol 1989, 134:1167–1173)*

Cytochrome-c-oxidase is the terminal enzyme of the respiratory chain. It is essential for respiratory function because it irreversibly transfers electrons of the chain to molecular oxygen.<sup>1</sup>

In recent years, since the report of van Biervliet et al.,<sup>2</sup> it has become apparent that deficiency of cytochrome-c-oxidase is one of the most common defects of the respiratory chain and is associated with various benign and fatal disorders.<sup>3–7</sup> Especially chronic progressive external ophthalmoplegia (CPEO), a special entity of mitochondrial

myopathies,<sup>8–10</sup> is associated with benign cytochrome-c-oxidase deficiency, affecting a relatively minor portion of skeletal muscle fibres.<sup>11–20</sup>

We recently demonstrated similar defects in the heart muscle of a patient with Kearns-Sayre syndrome,<sup>17</sup> a special variant of CPEO with an early onset characterized by, among other features, paralysis of the external ocular muscle, progressive proximal myopathy, pigmentary degeneration of the retina, and cardiac disturbances, especially of the conductive system.

The pathogenesis of cytochrome-c-oxidase deficiency and especially of the focal defects in CPEO, however, is still poorly understood. Keeping in mind that disturbances of mitochondrial function may be an important factor of cellular aging in senescence,<sup>21–23</sup> one attractive hypothesis could be that cytochrome-c-oxidase deficiency in CPEO is also related to cellular aging. This assumption is corroborated in the present study, in which an age-associated occurrence of cytochrome-c-oxidase deficient cardiomyocytes is described in both normal and diseased hearts. Cytochrome-c-oxidase deficiency in Kearns-Sayre syndrome and in CPEO might therefore develop in the course of accelerated cell aging.

## **Material and Methods**

The study group consisted of 140 men up to 97 years of age who died before or shortly after hospitalization. Patients suffering from malignant disease or receiving chemotherapy are not included. In 80% of the cases sudden death occurred either by central nervous dysregulation (52%) due to traumatic brain damage caused by accidents, subdural hematoma, sinus venous thrombosis,

---

Supported by grants from the Deutsche Forschungsgemeinschaft.

Presented in part at the 5th European Bioenergetics Conference (EBEC) in Aberystwyth, Great Britain, August 1988.

Accepted for publication February 15, 1989.

Address reprint requests to J. Müller-Höcker, Pathologisches Institut der Universität, Thalkirchner Str. 36, 8000 München 2, FRG.

**Table 1. Hearts with Cytochrome-c-Oxidase Deficient Cardiomyocytes: Age Dependency of Defect Expression**

	Age (m)	0-7	14-20	21-30	31-40	41-50	51-60	61-70	71-80	81-97	Σ
Total		0/7	5/10	13/18	14/17	29/31	14/14	6/6	16/16	21/21	118/140
Normal hearts		0/7	5/10	10/14	11/13	8/9	5/5	3/3	6/6	2/2	50/69
Hypertrophy		-	-	3/4	3/4	9/10	3/3	1/1	5/5	-	24/27
Coronary sclerosis		-	-	-	-	4/4	3/3	-	3/3	9/9	19/19
Hypertrophy coronary sclerosis		-	-	-	-	8/8	3/3	2/2	2/2	10/10	25/25

and infarction, or by cardiovascular failure (28%) due to coronary heart disease, pulmonary embolism, or acute blood loss. In the remaining cases, causes of death were bronchopneumonia, cerebral palsy, drowning, and intoxications, generally in combination with cardiovascular disease. Autopsy specimens from the left heart ventricle were deep frozen in liquid nitrogen for enzyme histochemical studies between 5 and 96 hours after death (generally between 15 and 30 hours).

Cytochrome-c-oxidase activity was determined histochemically on frozen sections, as described previously,<sup>24</sup> without the addition of hydrogen peroxide. From every heart, one section (minimum area, 0.8 sq cm; maximum area, 2 sq cm; average area, 1.3 sq cm) was studied for the presence of enzyme deficient cardiomyocytes (×25). To quantify the results, the number of defects/sq cm (defect density) was determined in defined rectangular areas. For statistical analysis, the test of Kruskal and Wallis was applied (with the support of Prof. D. Hölzel, Institut für medizinische Informationsverarbeitung, Statistik und Biomathematik, Universität München). In addition, in five selected cases, cytochrome-c-oxidase was studied at the electron microscopical level. The histochemical activity of succinate dehydrogenase was determined according to Lojda et al.<sup>25</sup>

## Results

Sixty-nine hearts revealed no pathomorphologic alterations. In 27 hearts, heart hypertrophy without coronary

arteriosclerosis was present (heart weight up to 510 g). Nineteen hearts showed coronary arteriosclerosis without heart hypertrophy (heart weights below 350 g for men, 330 g for women) and 25 hearts exhibited both heart hypertrophy and coronary arteriosclerosis (Table 1).

In 118 of the 140 heart specimens, defects of cytochrome-c-oxidase activity were detected (Table 1); the defects being present in 50 of 69 normal hearts and in 68 of 71 hearts with pathomorphologic alterations. In the second decade of life, the defects occurred sporadically. From the sixth decade on, however, the defects were regularly observed in every case.

Similarly, as the number of hearts with enzyme defects increased with age, the number of defects/sq cm heart (defect density) also showed an age-dependent increase. The median value of defect density rose from 2 to 3 in the second and third decade up to 50 defects/sq cm in advanced age (Table 2), especially in the seventh decade and later. The increase of defect density was expressed both in hearts with and without pathomorphologic alterations approximately to the same degree.

Statistical analysis by the test of Kruskal and Wallis for ranks variance analysis (H-Test) revealed a highly significant age-dependent increase of defect density (H-value, 34.93). Furthermore, significant results were obtained between the lower age groups (14 to 30, 30 to 50 years) and the advanced age group (51 to 97 years). No significant differences existed between normal hearts and pathologic hearts in the various age groups. There was no correlation between the rate of defect expression and the time elapsed after death. The highest defect density (158/sq cm) occurred in the advanced age group 9 hours post mortem.

Conversely, only 28 defects/sq cm were observed in another case of the same age group despite an elapse of 72 h.p.m. After 4 days of autolysis, 33 defects/sq cm were noted in the heart of a septuagenarian. There was no appreciable difference in the time elapsed in the study group below and the one above 50 years of age, most hearts being studied between 15 and 30 h.p.m. After this period of autolysis the maximal defect density was 8 defects/sq cm in the lower age group and 131 defects/sq cm in the higher age group. Even after 85 h.p.m. the defect density did not rise above 2/sq cm in the lower age group.

**Table 2. Cytochrome-c-Oxidase Deficient Cardiomyocytes: Defect Density\***

	Age	14-30	31-50	51-97
Total		2.4 0.4-5.3	4.4 1-13.3	50 2-158
Normal hearts		2.2 0.4-5.3	5 1-12.5	52 17-133
Hypertrophy		3 0.8-4	4.5 2-10	51.3 9-66
Coronary sclerosis		-	2.1 1-9.5	52 8-158
Hypertrophy/ coronary sclerosis		-	4 2.5-13.3	36 2.6-158

\* Defects/sq cm (median, minimum, maximum).

Defects of succinate dehydrogenase were visualized to a far lower degree than those of cytochrome-c-oxidase. In the hearts with coronary arteriosclerosis or heart hypertrophy, the defects occurred most often (maximal defect density 14/sq cm).

### Morphology of Cytochrome-c-Oxidase Deficient Heart Muscle Cells

Typically, loss of enzyme activity was always confined to single, randomly distributed cardiomyocytes. (Figure 1A). Occasionally, the defect was expressed in two to three neighboring heart muscle cells (Figure 1B). However, a defect of more than one muscle cell in a row was not observed. In most of the heart muscle cells there was a complete lack of enzyme activity; occasionally, however, some residual activity was present. As shown by ultramicroscopy, the defect always involved all the mitochondria of a cell and ended abruptly at the intercalated discs of the neighboring cardiomyocytes (Figure 2A). The ultrastructure of the affected heart muscle cells (studied in five cases) was inconspicuous, as far as it may be judged from autopsy tissue. No focal loss of myofibrils and no morphologically obvious increased content of mitochondria or of lipofuscin was seen. Occasionally some degree of cellular atrophy was observed (Figure 2B). Neither at electron microscopy nor at light microscopy were there signs of ischemic cell damage. There was no loss of cross-striation and no cellular infiltrate.

### Discussion

Mammalian cytochrome-c-oxidase is a complex enzyme, composed of 13 subunits.<sup>26,27</sup> The larger subunits (I to III) are encoded on the mitochondrial genome and synthesized in the mitochondria itself. They contain the four redox centers (2 hem groups and 2 copper ions) and are essential for the catalytic function of the enzyme. The 10 smaller subunits (IV to VIII) are transcribed from the nucleus and are supposed to exert a regulatory influence on the enzyme function.<sup>1,28</sup>

### Deficiency of Cytochrome-c-Oxidase

Deficiency of cytochrome-c-oxidase is a characteristic finding of primary mitochondrial disorders, especially of mitochondrial myopathies and encephalomyopathies, often with severe enzyme deficiency and a fatal outcome in early childhood. In CPEO, a typical mitochondrial myopathy of later onset, focal cytochrome-c-oxidase deficiency in single but not all fibers is now well established.





Figure 1. Cytochrome-c-oxidase, enzyme histochemistry. Normal aged heart (without coronary sclerosis, hypertrophy). A: An isolated cardiomyocyte lacks enzyme activity ( $\uparrow$  lipofuscin granules). B: Neighboring cytochrome-c-oxidase-deficient heart muscle cells with some residual enzyme activity (A,  $\times 1600$ ; B,  $\times 960$ ).

We recently observed similar defects in the heart of a 26-year-old patient with Kearns-Sayre syndrome, a variant of CPEO.<sup>17</sup> The detection of randomly distributed cytochrome-c-oxidase deficient cardiomyocytes, especially in the heart of elderly men without any signs of a mitochondrial cytopathy, is the significant finding of the present investigation. The expression of the enzyme defect was not dependent on preexisting pathologic alterations of the heart and therefore was present both in structurally normal hearts and in hearts with coronary sclerosis or heart hypertrophy. Furthermore, the defects were not limited to the advanced age groups, but were already present, although to a lesser degree, in younger patients. Therefore, these results are most consistent with an age-dependent process. Neither heart hypertrophy, coronary sclerosis, nor both variables in conjunction had a statistically significant amplification effect on the defect expression rate. Nevertheless, such an effect cannot be ruled out absolutely, more so as the highest defect density (158/sq cm), was noted in the group of coronary arteriosclerosis. With



**Figure 2.** Cytochrome-c-oxidase, ultracytochemistry. **A:** Enzyme-deficient heart muscle cell with inconspicuous ultrastructure. The enzyme defect is strictly limited to one cardiomyocyte ending exactly at the intercalated disc (↑) of the neighboring heart muscle cell. **B:** Enzyme deficient cardiomyocyte with cellular atrophy (x) (A,  $\times 2000$ ; B,  $\times 1150$ ).

respect to the high range of individual values, only a longitudinal study design (which for ethical reasons remains hypothetical) could clarify this point.

The peculiarity of the alteration is illustrated by the strict limitation of the defect to single cardiomyocytes, with the defect always ending abruptly at the intercalated discs. Furthermore, there was no obvious alteration of the ultrastructure of the defective cardiomyocytes with respect to the content of mitochondria, myofibrils or lipofuscin, as far as may be judged from autopsy tissue and without morphometric analysis.

### *Specificity of the Lesion*

With respect to the generally normal structure, nonspecific degenerative influences as in heart hypertrophy or cardiomyopathies<sup>29,30</sup> are of no obvious importance for

the manifestation of the enzyme defect. Furthermore, various observations indicate that the described defects of cytochrome-c-oxidase are specific and cannot be attributed to autolytic lesions, which do occur after death.

The results demonstrate that the number of defects do not increase with, and are therefore independent of, the time elapsed since death. This is also illustrated by a case of Kearns-Sayre syndrome in a young man with a mitochondrial cardiomyopathy seen already after 3 h.p.m.<sup>17</sup> and a rather high defect density of 90/sq cm. In the rat heart enzyme, histochemically detectable activity of cytochrome-c-oxidase remains unaltered up to 4 days after death.<sup>31</sup> Biochemical enzyme studies performed in rat liver mitochondria aged *in vitro* for 120 hours reveal only minor losses of the enzyme's activity.<sup>32</sup> Moreover, cytochrome-c-oxidase, along with succinate dehydrogenase, is the most stable complex of the respiratory chain,

showing no early loss of activity in the ischaemic heart.<sup>33,34</sup> In addition, post mortem enzyme defects caused by autolysis are known to occur as patchy defects<sup>31</sup> and not as unicellular lesions. Also, no correlation existed between the cause of death and the rate of defect expression. There were, for example, no statistically significant differences between the defect density in old men with normal hearts dying of noncardiac cause and men dying because of coronary arteriosclerosis.

### *Alteration of Heart Function and Structure During Aging*

Aging of the heart starts in approximately the third decade of life. The aging process involves a decrease of the maximal heart rate and the ejection volume, including the ejection fraction. The heart aging process also involves an increase of the end diastolic filling pressure and volume, an increase of heart wall stiffness (reduced compliance), a prolongation of contraction and relaxation time, a retarded sequestration of calcium in the sarcoplasmic reticulum, a decrease of catecholamine sensitivity and conduction velocity, as well as alterations of the iso-enzyme pattern of myosin ATPase.<sup>35-43</sup>

Morphologically, aging is accompanied by the accumulation of lipofuscin, originating from lipid peroxidation and polymerisation of membrane phospholipids derived from mitochondria, for example. In old animals, a reduced content of ribosomes as well as an increased content of lipids, glycogen, lysosomes, or of autophagocytic vacuoles has been described. Mitochondria may show myelinated figures as well as vacuolization of their matrix, and structural alterations of the cristae have been recorded.<sup>44,45</sup> Quantitative data of mitochondria reveal conflicting results.<sup>44</sup> On the whole, however, there appears to be a tendency toward an increased number of mitochondria with a reduced volume, thus leaving the volume fraction/cell of mitochondria rather constant in the aging cardiomyocyte.

Functional alterations of mitochondria, including loss of respiratory control, a decrease of P/O ratio, and a 30% reduction of the activity of adenine nucleotide translocase, are known to occur in aged mitochondria.<sup>46,47</sup> Furthermore, a decrease of cytochrome-c-oxidase activity has been reported in aging hearts of rats<sup>48,49</sup> and in other organs,<sup>50</sup> as well as in cultures of *podospora anserina*.<sup>51</sup> On the whole, however, conflicting data exist concerning the activity of respiratory enzymes during senescence.<sup>50,52</sup>

Concerning the pathogenesis of the unicellular defects of cytochrome-c-oxidase described here, the random distribution of the deficient heart muscle cells is most consistent with a stochastic process.<sup>53</sup> In this respect

above all, free radical injury of membranes, enzyme proteins, and probably of mitochondrial DNA itself (by superoxide and hydroxyl radicals that may be generated in the respiratory chain, for example)<sup>21,22,54-61</sup> are of special interest. The exact mechanism, however, remains to be investigated. Preliminary immunohistochemical data indicate that the loss of enzyme activity is accompanied by a reduced content of enzyme protein.

As for the significance of the defects, they may be associated with age-related loss of cardiac muscle cells<sup>62-65</sup> and the reduction of myocardial contractile ability in senescence. Furthermore, the presence of a rather high degree of such defects in the heart of a young man with a mitochondrial myocardiomyopathy<sup>17</sup> in the course of CPEO might indicate that premature cell aging is of pathogenetic importance in this special disorder.

This hypothesis is substantiated further by the fact that defects, similar to those in CPEO but to a lesser degree, also occur in the skeletal muscle and additionally in the diaphragm of men without mitochondrial or muscular diseases.<sup>66</sup> This situation, therefore, is similar to the presence of senile plaques even in the normal brain and their increased manifestation in age-associated Alzheimer dementia.

### *References*

1. Kadenbach D, Kuhn-Nentwig L, Büge U: Evolution of a regulatory enzyme: Cytochrome-c-oxidase (complex IV). *Curr Top Bioenergetics* 1987, 15:113-161
2. Van Biervliet J, Bruinvis L, Ketting D, De Bree PK, van der Heiden C, Wadman SK, Willems JL, Bookelman H, van Haelst U, Monnens LAH: Hereditary mitochondrial myopathy with lactic acidemia, a DeToni-Fanconi-Debré syndrome, and a defective respiratory chain in voluntary striated muscles. *Ped Res* 1977, 11:1088-1093
3. Di Mauro S, Hays AP, Eastwood AB: Different clinical expressions of cytochrome-c-oxidase deficiency. *Mitochondrial Pathology in Muscle Diseases*. Edited by G Scarlato, C Cerri. Padua: Piccin Medical Books, 1983, pp 111-129
4. Di Mauro S, Bonilla E, Zeviani M, Bresolin N, Nakagawa M, Miranda AF, Moggio M: Cytochrome-c-oxidase deficiency. *Biochem Soc Trans* 1985, 13:651-653
5. Di Mauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo DC: Mitochondrial myopathies. *Ann Neurol* 1985, 17:521-538
6. Di Mauro S, Zeviani M, Servidei S, Bonilla E, Miranda AF, Prele A, Schon EA: Cytochrome oxidase deficiency: Clinical and biochemical heterogeneity. *Ann NY Acad Sci* 1987, 488:19-32
7. Di Mauro S, Bonilla E, Zeviani M, Rizzuto R, Lombes A, Nakase H, Miranda A, Schon E: Molecular defects in cytochrome oxidase in mitochondrial diseases. *J Bioenerg Biomembr* 1988, 20:353-364
8. Bastiaansen LAK, Joosten EMG, de Rooij JAM, Hommes OR, Stadhouders AM, Jaspars HHJ, Veerkamp JH, Bookel-

- man H, van Hinsbergh VWM: Ophthalmoplegia-plus, a real nosological entity. *Acta Neurol Scand* 1978, 58:9-34
9. Berenberg RA, Pellock JM, Di Mauro S, Schotland DL, Bonilla E, Eastwood A, Hays A, Vicale CT, Behrens M, Chutorian A, Rowland LP: Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? *Ann Neurol* 1977, 1:37-54
  10. Rowland LP, Hays AP, Di Mauro S, De Vivo SC, Behrens M: Diverse clinical disorders associated with morphological abnormalities of mitochondria, Mitochondrial pathology in muscle diseases. Edited by G Scarlato, C Cerri. Padua: Piccin, 1983, pp 142-158
  11. Byrne E, Denef X, Trounce I, Burdon J: Partial cytochrome oxidase (aa<sub>3</sub>) deficiency in chronic progressive external ophthalmoplegia: Histochemical and biochemical studies. *J Neurol Sci* 1985, 71:257-271
  12. Hayes DJ, Lecky BRF, Landon DN, Morgan-Hughes JA, Clark JB: A new mitochondrial myopathy: Biochemical studies revealing a deficiency in the cytochrome b-c<sub>1</sub> complex (complex III) of the respiratory chain. *Brain* 1984, 107:1165-1177
  13. Johnson MA, Turnbull DM, Dick DJ, Sherratt HSA: A partial deficiency of cytochrome-c-oxidase in chronic progressive external ophthalmoplegia. *J Neurol Sci* 1983, 60:31-53
  14. Johnson MA, Kadenbach B, Droste M, Old SL, Turnbull DM: Immunocytochemical studies of cytochrome oxidase subunits in skeletal muscle of patients with partial cytochrome oxidase deficiencies. *J Neurol Sci* 1988, 87:75-90
  15. Müller-Höcker J, Pongratz D, Hübner G: Focal deficiency of cytochrome-c-oxidase in skeletal muscle of patients with progressive external ophthalmoplegia. *Virchows Arch (Pathol Anat)* 1983a, 402:61-71
  16. Müller-Höcker J, Stünkel S, Pongratz D, Hübner G: Focal deficiency of cytochrome-c-oxidase and of mitochondrial ATPase combined with loosely coupled oxidative phosphorylation in the skeletal muscle of a patient with progressive external ophthalmoplegia: An enzyme histochemical, immunocytochemical and fine structural study. *J Neurol Sci* 1985, 69:27-36
  17. Müller-Höcker J, Johannes A, Droste M, Kadenbach B, Pongratz D, Hübner G: Fatal mitochondrial cardiomyopathy in Kearns-Sayre syndrome with deficiency of cytochrome-oxidase in the cardiac and skeletal muscle: An enzyme-histochemical ultra-immunocytochemical fine structural study in longterm frozen autopsy tissue. *Virchows Arch (Cell Pathol)* 1986, 52:353-367
  18. Reichmann H, Johnson D, Turnbull M, Sherratt HSA: The cytochemical determination of enzyme activities in single skeletal muscle fibres from patients with a partial deficiency of cytochrome oxidase. *Trans Biochem Soc* 1985, 13:730
  19. Sherratt HSA, Cartledge NEF, Johnson MA, Turnbull DM: Mitochondrial myopathy with partial cytochrome oxidase deficiency and impaired oxidation of NADH-linked substrates. *J Inher Metab Dis* 1984, 7(suppl 2):107-108
  20. Turnbull DM, Johnson MA, Dick DJ, Cartledge NEF, Sherratt HSA: Partial cytochrome c oxidase deficiency in skeletal muscle of patients with progressive external ophthalmoplegia. *J Neurol Sci* 1985, 71:257-271
  21. Fleming JE, Miquel J, Cottrell SF, Yengoyan LS, Economos AC: Is cell aging caused by respiratory-dependent injury to the mitochondrial genome? *Gerontology* 1982, 28:44-53
  22. Harman A: Free radical theory of aging: Consequences of mitochondrial aging. *Age* 1983, 6:86-94
  23. Miquel J, Economos AC, Fleming J, Johnson JE: Mitochondrial role in cell aging. *Exper Gerontol* 1980, 15:575-591
  24. Müller-Höcker J, Pongratz D, Deufel Th, Trijbels JMF, Endres W, Hübner G: Fatal lipid storage myopathy with deficiency of cytochrome-c-oxidase and carnitine. *Virchows Arch (Pathol Anat)* 1983b, 339:11-23
  25. Lojda Z, Gossrau R, Schiebler TH: *Enzymhistochemische Methoden*. Berlin, Springer, 1976
  26. Kadenbach B, Jarausch J, Hartmann R, Merle P: Separation of mammalian cytochrome-c-oxidase into 13 polypeptides by a sodium dodecyl sulfate-gel electrophoretic procedure. *Ann Biochem* 1983, 129:517-521
  27. Kuhn-Nentwig L, Kadenbach B: Isolation and characterization of human heart cytochrome-c-oxidase. *J Bioenerg Biomembr* 1986, 18:307-314
  28. Kadenbach B: Regulation of respiration and ATP synthesis in higher organisms: Hypothesis. *J Bioenerg Biomembr* 1986, 18:39-54
  29. Ferrans VJ: Ultrastructure of degenerated muscle cells in patients with cardiac hypertrophy, Myocardial Failure. Edited by G Riecker, A Weber, J Goodwin. Berlin: Springer, 1977, pp 185-200
  30. Maron BJ, Ferrans VJ, Roberts WC: Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. *Am J Pathol* 1975, 79:387-434
  31. Penttilä A, Ahonen A: Electron microscopical and enzyme histochemical changes in the rat myocardium during prolonged autolysis. *Beitr Pathol* 1976, 157:126-141
  32. Da Silva PTP, Higuti IH, Stencel M, de Paiva Campello A, do Nascimento AJ: Studies on rat liver mitochondria: Enzyme activities in mitochondria preserved at 0-4°C. *Cell Biochem Funct* 1984, 2:49-52
  33. Mergner WJ, Mergner GW: Subcellular aspects of ischaemic heart disease: Studies on acute myocardial infarction, Cellular Pathology of Human Disease. Edited by BFT Trump, A Langer, RT Jones. New York, Stuttgart: Fischer G, 1983, pp 271-308
  34. Rouslin W: Mitochondrial complexes I, II, III, IV, and V in myocardial ischaemia and autolysis. *Am J Physiol (Heart Circ Physiol)* 1983, 13:743-748
  35. Bender F: Klinik des alternden Herzen. *Z. Kardiol* 1985, 74 (suppl 7):49-54
  36. Ehsani AA: Cardiovascular adaptations to exercise training in the elderly. *Federation Proc* 1987, 46:1840-1843
  37. Gerstenblith G, Lakatta EG, Weisfeldt M: Age changes in myocardial function and exercise response. *Progr Cardiovasc Dis* 1976, 19:1-21
  38. Harris R: Cardiac arrhythmias in the aged, *Cardiology and*

39. Hollmann W, Rost R, Liesen H: Die Bedeutung des Sports für das Herz des älteren Menschen. *Z Kardiol* 1985, 74 (suppl 7):39-48
40. Lakatta EG: Alterations in the cardiovascular system that occur in advanced age. *Fed Proceed* 1979, 38:163-167
41. Lakatta EG: Some newer perspectives on how the heart ages, *Cardiology and Aging*. Edited by D Platt. Stuttgart: Schattauer, 1982, pp 161-175
42. Lakatta EG: Cardiac muscle changes in senescence. *Ann Rev Physiol* 1987, 49:519-531
43. Port S, Cobb F, Coleman RE, Jones RH: Effect of age on the response of the left ventricular ejection fraction to exercise. *N Engl J Med* 1980, 303:1133-1137
44. Frenzel H: Das Herz im Alter. Licht- und elektronenmikroskopische Befunde. *Z Kardiol* 1985, 74(suppl 7):17-25
45. Hutchins GH: Structure of the ageing heart, *The Aging Heart*. Edited by ML Weisfeldt. New York: Raven Press, 1980, pp 7-23
46. Nohl H, Breuninger V, Hegner D: Influences of mitochondrial radical formation on energy-linked respiration. *Eur J Biochem* 1978, 90:385-390
47. Nohl H, Krämer R: Molecular basis of age-dependent changes in the activity of adenine nucleotide translocase. *Mech Aging Dev* 1980, 14:137-144
48. Abu-Erreish GM, Sanadi DR: Age related changes in cytochrome concentration of myocardial mitochondria. *Mech Aging Dev* 1978, 7:425-432
49. Nohl H: Oxygen radical release in mitochondria: Influence of age. *Mod Ag Res* 1986, 8:77-98
50. Rothstein M: *Biochemical approaches to ageing*. New York: Academic Press, London, 1982
51. Belcour L, Bege O, Keller AM, Vierny C: Does senescence in *podospora anserina* result from instability of the mitochondrial genome? *Mitochondrial Genes*. Edited by PP Slonimski, P Borst, C Attardi. Cold Spring Harbor NY: Cold Spring Harbor Lab, 1982, pp 415-422
52. Wilson PD: Enzyme changes in ageing mammals. *Gerontology* 1973, 19:79-125
53. Strehler B: Genetic instability as the primary cause of human ageing. *Exp Gerontol* 1986, 21:283-319
54. Freeman BA, Crapo JD: Biology of disease: Free radicals and tissue injury. *Lab Invest* 1982, 47:412-426
55. Fridovich I: Superoxide radical: An endogenous toxicant. *Ann Rev Pharmacol Toxicol* 1983, 23:239-257
56. Halliwell B: Oxygen radicals: A common sense look at their nature and medical importance. *Med Biol* 1984, 62:71-77
57. Halliwell B, Gutteridge JMC: The importance of free radicals and catalytic metals in human diseases. *Mol Aspects Med* 1985, 8:89-193
58. Hegner D: Age-dependence of molecular and functional changes in biological membrane properties. *Mech Aging Dev* 1980, 14:101-118
59. Nohl H: The biochemical mechanism of the formation of reactive oxygen species in heart mitochondria, *Advances in Studies on Heart Metabolism*. Edited by CM Caldarera, P Harris. Bologna: Clueb, 1982, pp 413-421
60. Nohl H, Hegner D: Do mitochondria produce oxygen radicals in vivo? *Eur J Biochem* 1978, 82:563-567
61. Vladimirov YA, Olenev VI, Suslova TB, Cheremisina ZP: Lipid peroxidation in mitochondrial membrane. *Adv Lipid Res* 1980, 17:173-249
62. Anversa R, Hiler B, Ricci R, Gueideri G, Olivetti G: Myocyte cell loss and myocyte hypertrophy in the ageing rat heart. *J Am Coll Cardiol* 1986, 8:1441-1448
63. Davies MJ, Pomerance A: Quantitative study of ageing changes in the human sinoatrial node and internodal tracts. *Br Heart J* 1972, 34:150-152
64. Fujino M, Okada R, Arakawa K: The relationship of ageing to histological changes in the conduction system of the normal human heart. *Jpn Heart J* 1983, 24:13-20
65. Hecht FM: Studie über quantitative Altersveränderungen am Hisschen Bündel des Menschen. *Virchows Arch A (Pathol Anat)* 1980, 386:343-356
66. Müller-Höcker J: Morphologie, Cytochemie und Immunhistochemie des Cytochrom-c-oxidase Mangel. *Verh Dtsch Ges Path* 1988, 72:552-565

### Acknowledgment

The author thanks Mrs. A. Scheiber, Mrs. C. Holzhäuser for valuable technical assistance, Mrs. P. Tränkel, and especially Ms. D. Raabe, for skillfully typing the manuscript, and Prof. V. Herzog (Institut für Zellbiologie der Universität München) for reviewing the manuscript and for his constructive comments.